SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
LUCERNE, Switzerland and NEW DELHI, Oct. 13, 2026 /PRNewswire/ -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting stents (DES) in patients with complex coronary artery disease. Designed to generate comparative evidence, S
Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.
Read full story on publisher site →